A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
about
Inhibition of microRNA function by antimiR oligonucleotidesIn vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.Crystallographic studies of chemically modified nucleic acids: a backward glanceStabilizing contributions of sulfur-modified nucleotides: crystal structure of a DNA duplex with 2'-O-[2-(methoxy)ethyl]-2-thiothymidines2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencingCurrent understanding of interactions between nanoparticles and the immune systemAdvanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the BrainStructure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery systemNMR structure of an -L-LNA:RNA hybrid: structural implications for RNase H recognitionAmides are excellent mimics of phosphate internucleoside linkages and are well tolerated in short interfering RNAsMicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal CancersPre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategyProgress toward in vivo use of siRNAs-IISilencing disease genes in the laboratory and the clinicPharmacokinetics and Toxicity in Rats and Monkeys of coDbait: A Therapeutic Double-stranded DNA Oligonucleotide Conjugated to CholesterolAntisense properties of tricyclo-DNAEffects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.Development of microRNA therapeutics is coming of age.Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugsPTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice.Translational considerations for cancer nanomedicine.Gene therapy for HIV.Antisense oligonucleotide treatments for psoriasis.Potential roles of antisense technology in cancer chemotherapy.Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.Reduction of lipocalin-type prostaglandin D synthase in the preoptic area of female mice mimics estradiol effects on arousal and sex behaviorRNA-based gene therapy for HIV infection.Advances ofcapillary electrophoresis in clinical and forensic analysis (1999-2000).Telomerase inhibition, oligonucleotides, and clinical trials.Unexpected side products in the conjugation of an amine-derivatized morpholino oligomer with p-isothiocyanate benzyl DTPA and their removal.Antisense oligonucleotide therapy for urologic tumors.Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells.Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection.Towards Fluorescence In Vivo Hybridization (FIVH) Detection of H. pylori in Gastric Mucosa Using Advanced LNA Probes.Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen.Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects.Antisense Oligonucleotide-Mediated Transcript Knockdown in ZebrafishBinding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9.Oligonucleotides and polyribonucleotides: a review of antiviral activity.
P2860
Q21198757-7AA0C4D3-B397-42E5-B033-43AC35E33C9BQ24530841-AE344333-2F67-4812-B727-F9C6FDDA0EC2Q24608092-30C6E375-2D16-4552-B668-238491FE096FQ24815181-FA74FD7A-1B25-42E7-A79A-09636FA7C927Q25255757-F28D6675-7F03-48BF-9D50-A0644CA7B736Q26345204-7D007133-1742-40C4-BBD6-33D0F844C565Q26770355-A03683A4-F2F7-428E-86F1-BFA016789928Q27004381-FA0B6B58-B129-427D-AB3A-2CA60855E957Q27642301-CC00D151-3499-4037-AFBE-562B0CB2B3F5Q27683696-A1B9ACEB-1DC5-47F2-9FA1-BC8A7DEFD814Q28076754-9C75A2EB-F742-4EB8-81C1-F6D9F46DF105Q28081577-D101EC1C-C420-48CD-BFEC-BD8815203D18Q28255877-490FA957-F164-485B-9BEA-AE02801B22DBQ29039090-BB2A314E-DF90-437F-8721-DD430E6A37B4Q30523973-1E9D015B-F8D8-4058-8BEE-F836456C6B76Q31089384-EDB84565-6291-4963-8AE6-83ED4B453BA7Q33572902-2EBF1E3B-559C-4160-ABB5-76D613B518B5Q33991443-FBBAC18E-6AB2-4C28-9577-2968FED02A6AQ34011214-9EF87160-CF05-4631-A7D5-BF8A65031AE4Q34038299-CB80E2E0-899A-4BCB-B8F7-5B0DAEE8D5DAQ34065785-A72CA408-A7F1-495E-9CCA-95700E7A6F78Q34208320-4052B9D2-2254-4C76-8F43-467A750A3981Q34284377-E657CE62-BB2E-4A29-B737-79028005A886Q34293601-C9AB8C15-B355-4C08-BF58-12A9D61B656AQ34367048-8525C09E-2F3F-4C4F-A0DE-56E597310DF9Q34393190-7F599599-C53D-4C24-804A-09A46FB3CB52Q34459382-AC36C498-642B-42B9-930E-E3978E65E6A8Q34514906-954D4A3C-181F-4681-A87F-54B354D251E0Q34535686-C01495D4-9CEC-4450-9C83-74674C300882Q34644344-E1333A5E-FA3C-4632-A459-DE834107949AQ35049576-BE85C44A-C272-4B77-8268-1839A3A6FBF3Q35089996-8F52C8EE-48C2-4175-B22D-4DFD1F11C23CQ35159206-FCFC777C-12AF-4804-AD8E-A8E052CD431DQ35615550-379B478B-7CFA-4039-93B0-EC0AF988F370Q35635250-4B9749B5-03F7-47B0-9AEB-EDCAD757A9C4Q35643050-74180A91-9C4D-456D-9997-7BED36A0F6C9Q35763466-BC4F75BA-94BA-4AEA-AF5F-9900DB7FA5BBQ35799184-1B21C1F9-EB67-4CF1-8009-AE411FD83EF9Q36117550-E8E1D065-BDFD-4634-A9C0-575435E97AD9Q36124734-A30E407A-C111-4BF7-AF8E-61E1BC9C6B9C
P2860
A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A review of the issues in the ...... te antisense oligonucleotides.
@ast
A review of the issues in the ...... te antisense oligonucleotides.
@en
type
label
A review of the issues in the ...... te antisense oligonucleotides.
@ast
A review of the issues in the ...... te antisense oligonucleotides.
@en
prefLabel
A review of the issues in the ...... te antisense oligonucleotides.
@ast
A review of the issues in the ...... te antisense oligonucleotides.
@en
P1476
A review of the issues in the ...... te antisense oligonucleotides.
@en
P2093
P356
10.1016/S0167-4781(99)00140-2
P407
P577
1999-12-01T00:00:00Z